Celldex Therapeutics, Inc. (CLDX)

55.21
NASDAQ
Prev Close 55.99
Day Low/High 54.65 / 56.14
52 Wk Low/High 11.55 / 56.17
Exchange NASDAQ
Shares Outstanding 46.48B
Market Cap 2.60B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Best Buys for 2021? Look at Small-Cap Biotechs

Best Buys for 2021? Look at Small-Cap Biotechs

Eight favorite stock ideas in the small-cap biotech space.

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.

Market Wrap: Stocks Retreat on China Devaluation

Market Wrap: Stocks Retreat on China Devaluation

However, utilities and some technology names bucked the trend.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

Many Ways to Win

Many Ways to Win

Try to find bullish charts that don't all look the same.

No Reason to Jump Long

No Reason to Jump Long

I'm content to sit in cash and wait for a trigger.

A Brick Wall for Bulls

A Brick Wall for Bulls

The S&P is putting up strong resistance that has withstood several attacks today.

Fitz Bits: Careful With Those Highfliers

Fitz Bits: Careful With Those Highfliers

In other words, don't overstay your welcome.

Opportune Selloffs

Opportune Selloffs

This action makes it a good time to add to two quality names.

Setting Up a Pair of Plays

Setting Up a Pair of Plays

Qualcomm seems to be breaking out of a bullish flag, and Celldex has a fantastic chart.

Some Weekend Folding Money

Some Weekend Folding Money

I'm content to head into the weekend with my short-term book mostly on the cash side.

5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Blackberry's Flying Circus, Foolish Filmmaker, Celldex Shenanigans, Benmosche's Big Mouth and Chrysler's Conundrum highlight Gregg Greenberg's list of dumb things on Wall Street this week.

Biotech Breakouts

Biotech Breakouts

Favorable charts for Celldex, Repligen and Arrowhead Research.

Celldex price target raised at Jefferies

Off the Charts

Off the Charts

Maintain a long-side bias until composure changes.

Off the Charts

Off the Charts

The S&P is in an uptrend but the market is in digestion mode.

Feels Like a Bear Market

Feels Like a Bear Market

The best thing to do is get out of the way and let it play out.

The Action Has Shifted

The Action Has Shifted

And the close put an exclamation point on it.

Stock-Picking Wins the Day

Stock-Picking Wins the Day

There's still speculative interest out there.

Bulls Deserve Respect

Bulls Deserve Respect

It really is amazing how this market keeps roaring back.

Too Much Chop

Too Much Chop

I'm eager to enter new trades but leery of forcing things.

Momentum Is Lacking

Action is a mixed bag so far.

The Next Big Thing In Biotech: Celldex

The Next Big Thing In Biotech: Celldex

Adam Feuerstein, Sr. Columnist for TheStreet, says Celldex Therapeutics is the next big thing in biotech.

Next Big Thing in Biotech: Cancer Drug Stocks

Next Big Thing in Biotech: Cancer Drug Stocks

Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.

The Next Big Thing in Biotech: BIO CEO Conference

The Next Big Thing in Biotech: BIO CEO Conference

Adam Feuerstein, senior columnist, explains why the BIO CEO Conference is the next big thing in biotech.